Icatibant Teva

Icatibant, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and type II in affected patients.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution focused on the EU market. The company adheres to stringent quality standards and provides cold‑chain logistics for injectable products.

Icatibant is employed in the management of hereditary angioedema (HAE), a rare genetic disorder, by blocking the bradykinin pathway that causes rapid swelling of skin and mucosal tissues.

Hereditary angioedema type I: rapidly reduces swelling and pain during acute attacks. Hereditary angioedema type II: alleviates symptoms of sudden edema episodes. Hereditary angioedema (all types): provides prompt relief of airway and peripheral swelling. Hereditary angioedema with airway involvement: helps prevent life‑threatening laryngeal edema during attacks.

The most frequently reported adverse reactions to Icatibant are related to its subcutaneous administration and its pharmacologic activity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache. - Dizziness: brief episodes of light‑headedness. - Flushing: temporary warmth and reddening of skin.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe angioedema: worsening of swelling despite treatment. - Hypotension: marked drop in blood pressure. - Infection at injection site: cellulitis or abscess formation.

Before using Icatibant, clinicians should consider several safety aspects to minimize risk. - Renal impairment: monitor dosing as the drug is primarily eliminated renally. - Hepatic impairment: use with caution; limited data in severe liver disease. - Pregnancy: safety not established; prescribe only if benefit outweighs risk. - Breastfeeding: unknown excretion; consider alternative therapy. - Concomitant ACE inhibitors or ARBs: may increase risk of angioedema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect can precipitate angioedema. - Angiotensin receptor blockers: similar risk of increased bradykinin‑mediated swelling. - Other bradykinin B2 antagonists: no added therapeutic benefit and may increase adverse events.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance and affect blood pressure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for heightened hypersensitivity. - Anticoagulants: monitor for bleeding if hypotension occurs.